Authored Content
Clinicians can support timely, sustainable rare disease care through institutionalized multi-disciplinary roles, strengthened referral networks, and the translation of clinical insights into policy and advocacy.
The recently launched CHI Catalogue signals payer endorsement of high-cost breakthrough therapies supported by strong clinical evidence, real-world data, and guideline endorsement.
Rare disease demands a unique playbook: The patient journey is rarely linear, the evidence base is often limited, and “rare” can have different meanings across settings and geographies. The third edition of our annual rare disease eBook explores the unique dynamics of the rare disease landscape and its implications for biotech stakeholders.
This third installment of our APAC rare disease series explores key enablers of achieving higher levels of multi-stakeholder collaboration in funding decisions for rare disease treatments.
In this first installment of our APAC rare disease series, we introduce the topic of multi-stakeholder collaboration and present a corresponding framework.
To enable global access to GLP-1 AOMs, manufacturers must demonstrate multidimensional value along the full care continuum and across the range of obesity linked-indications.